Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00501722
Registration number
NCT00501722
Ethics application status
Date submitted
13/07/2007
Date registered
16/07/2007
Date last updated
12/01/2009
Titles & IDs
Public title
Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites
Query!
Scientific title
SR121463B in Cirrhotic Ascites Treatment With Hyponatraemia: A Placebo-Controlled, Dose-Comparison Study
Query!
Secondary ID [1]
0
0
LTS5634
Query!
Secondary ID [2]
0
0
DFI4521
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Hypo~CAT
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ascites
0
0
Query!
Liver Cirrhosis
0
0
Query!
Condition category
Condition code
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
change in body weight, change in serum sodium
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
within 14 days
Query!
Secondary outcome [1]
0
0
abdominal girth and discomfort
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
14 days
Query!
Secondary outcome [2]
0
0
paracentesis
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
14 days
Query!
Secondary outcome [3]
0
0
trail-making test and quality of life
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
14 days
Query!
Eligibility
Key inclusion criteria
* Cirrhosis of the liver confirmed by ultrasound, endoscopic examination, or biochemical evidence
* Moderate or tense ascites
* Patients with hyponatremia, defined as a serum sodium concentration of =130 mmol/L
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/04/2004
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/03/2005
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
110
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Sanofi-Aventis Administrative Office - Cove
Query!
Recruitment postcode(s) [1]
0
0
- Cove
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
New Jersey
Query!
Country [2]
0
0
Argentina
Query!
State/province [2]
0
0
Buenos Aires
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Diegem
Query!
Country [4]
0
0
Canada
Query!
State/province [4]
0
0
Quebec
Query!
Country [5]
0
0
Croatia
Query!
State/province [5]
0
0
Zagreb
Query!
Country [6]
0
0
Czech Republic
Query!
State/province [6]
0
0
Praha
Query!
Country [7]
0
0
France
Query!
State/province [7]
0
0
Paris
Query!
Country [8]
0
0
Germany
Query!
State/province [8]
0
0
Berlin
Query!
Country [9]
0
0
Hungary
Query!
State/province [9]
0
0
Budapest
Query!
Country [10]
0
0
Italy
Query!
State/province [10]
0
0
Milano
Query!
Country [11]
0
0
Romania
Query!
State/province [11]
0
0
Bucuresti
Query!
Country [12]
0
0
Spain
Query!
State/province [12]
0
0
Barcelona
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective is to determine the optimal dose or range of doses of SR121463B for the treatment of ascites and the correction of hyponatraemia when used concomitantly with a standard dose regimen of spironolactone. The secondary objective is to determine the tolerability of different fixed doses of SR121463B over a 14 day treatment period in cirrhotic ascites. This Hypo\~CAT study is followed by a single-blind, placebo-controlled, one-year long-term safety extension (Expo\~CAT). The first extension is followed by another long-term study (PASCCAL-1).
Query!
Trial website
https://clinicaltrials.gov/study/NCT00501722
Query!
Trial related presentations / publications
Gines P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D; HypoCAT Study Investigators. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology. 2008 Jul;48(1):204-13. doi: 10.1002/hep.22293.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
ICD CSD
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT00501722
Download to PDF